ALD

ALD Equipment Market worth $6.2 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, October 31, 2023
Equipment, Hafnium(IV) oxide, MOSFET, Biomaterial, Audio power amplifier, Silicon carbide, AI, Defense, Quality control, Internet of things, ALD, Institute for Liquid Atomization and Spray Systems, Electronics, Cardiology, CVD, Reverse engineering, Power electronics, Corrosion, Zirconium dioxide, Flip chip, ASM International, EUGENE, Aerospace, Lighting, RF, Gallium arsenide, Automation, Silicon dioxide, Communication, LED, Growth, Gallium nitride, Gas Control Equipment Ltd, Oxide, Less, Chemical control, LAM, Tokyo Electron, Fluid mechanics, SOP, Indium phosphide, Neurology, BGA, Consumer electronics, Telecommunications, Video game, Medical device, Semiconductor, Region, Automotive industry

Oxide film type is expected to account for the largest market size of the ALD equipment market during the forecast period.

Key Points: 
  • Oxide film type is expected to account for the largest market size of the ALD equipment market during the forecast period.
  • Therefore, oxide films are expected to have the largest market size in the ALD equipment market.
  • Medical application is projected to register the highest CAGR in ALD equipment market during the forecast period.
  • Furthermore, strong presence of ALD equipment market players in the region creates growth opportunities for the ALD equipment in Asia Pacific.

ALD Equipment Market worth $6.2 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, October 31, 2023
Equipment, Hafnium(IV) oxide, MOSFET, Biomaterial, Audio power amplifier, Silicon carbide, AI, Defense, Quality control, Internet of things, ALD, Institute for Liquid Atomization and Spray Systems, Electronics, Cardiology, CVD, Reverse engineering, Power electronics, Corrosion, Zirconium dioxide, Flip chip, ASM International, EUGENE, Aerospace, Lighting, RF, Gallium arsenide, Automation, Silicon dioxide, Communication, LED, Growth, Gallium nitride, Gas Control Equipment Ltd, Oxide, Less, Chemical control, LAM, Tokyo Electron, Fluid mechanics, SOP, Indium phosphide, Neurology, BGA, Consumer electronics, Telecommunications, Video game, Medical device, Semiconductor, Region, Automotive industry

Oxide film type is expected to account for the largest market size of the ALD equipment market during the forecast period.

Key Points: 
  • Oxide film type is expected to account for the largest market size of the ALD equipment market during the forecast period.
  • Therefore, oxide films are expected to have the largest market size in the ALD equipment market.
  • Medical application is projected to register the highest CAGR in ALD equipment market during the forecast period.
  • Furthermore, strong presence of ALD equipment market players in the region creates growth opportunities for the ALD equipment in Asia Pacific.

Poxel Announces its Participation at Upcoming Scientific Conference

Retrieved on: 
Monday, October 2, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, NASH, Adrenoleukodystrophy, Scientific communication, ALD, AMPK, DSM-IV codes, Adenosine, Metabolism, Polycystic kidney disease, Fatty liver disease, R, ADPKD, Pharmacology, Autosome, Pharmaceutical industry, Vaccine, Euronext

POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it will participate at the upcoming 12th International Meeting on AMPK on October 4th, 2023.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it will participate at the upcoming 12th International Meeting on AMPK on October 4th, 2023.
  • Sophie Bozec, Executive Vice President, R&D Pharmacology and Scientific Communication at Poxel, will host a virtual presentation on “Direct AMPK Activation: From Preclinical to Clinical.
  • Perspectives in Rare Metabolic Diseases”.
  • The presentation will review Poxel’s molecule PXL770, which is a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, focused on rare diseases treatment, including adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD).

KULR and Forge Nano Form a Strategic Partnership for Enhanced Battery Safety and Performance

Retrieved on: 
Tuesday, September 26, 2023
U.S. Department of Energy, Office of Inspector General, Partnership, United States Department of Defense, U.S. Department of Defense Strategy for Operating in Cyberspace, ALD, Temperature, Cell, Recycling, Forge, KULR, NASA, SAN, MOU, Vehicle registration plates of Nepal, Silicon, Atomic layer deposition, OEM, Transport, News, NYSE, Safety, Mobile phone

SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a global leader in sustainable energy management, today announced that it has entered into a Memorandum of Understanding (MOU) with Forge Nano, a global leader in precision nanocoating technology. The strategic partnership, initially estimated at a $3.5 million to $5 million revenue opportunity, will combine KULR ONE Design Solutions offerings that include cell characterization and advanced automated battery cell screening capabilities with Forge Nano's proprietary Atomic Layer Deposition (ALD) coating process, tactically deploying the respective companies’ breakthroughs to OEM partners’ batteries with unmatched safety and efficiency.

Key Points: 
  • Last month, KULR announced it had secured a third order for automated battery cell screening services from NASA.
  • KULR believes that this partnership is well positioned to ensure that US-based battery production value chain redefines industry standards in battery safety and performance.
  • Forge Nano, with its commitment to piloting American-made batteries, has been at the forefront of exploring diverse silicon materials for enhanced battery application.
  • Earlier this year, Forge Nano raised $50 million to build out battery production lines to meet growing demand.

Poxel Reports Financial Results for First Half 2023 and Provides a Corporate Update

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Diabetes, ULF, Adrenoleukodystrophy, Prescription, Plasma, JPY, Patent, Patient, Serono, Merck, R, Estonia, POC, Pioglitazone, Sumitomo Group, Disease, Male, NASH, Pharmacokinetics, Sumitomo Pharma, EPO, Fatty liver disease, Leukodystrophy, Marshal of France, Rare, Kidney, Conference, Safety, Abstract, DPP4, ALD, JDS, Merck Serono, European Patent Office, Biomarker, DSM-IV codes, AMN, IRIS, Scientific communication, United States patent law, SGLT2, VLCFA, EUR, European Patent Convention, Pharmacology, TZD, Pharmaceutical industry, Medical device, Imeglimin, Euronext

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.
  • For the Sumitomo Pharma FY 2023, as a conservative assumption in line with Sumitomo Pharma’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • This recently issued patent provides additional protection through 2041, with the potential for an additional 5 years through patent term extension.

EveryLife Foundation Study Measures Economic Impact of Delayed Diagnosis of Rare Diseases

Retrieved on: 
Thursday, September 14, 2023
Research, Congressional News, Views, Public Policy, Government, Healthcare Reform, Health, State, Local, General Health, Other Science, Science, Bureau of Labor Statistics, Workforce, Medicine, Medicaid, Life, New Era, ALD, Bureau, Survival, Quality of life, Pfizer, Glycogen storage disease type II, Pharmacy, Anatomical pathology, Diagnosis, Patient engagement in Canada, Occupational therapy, Genetic counseling, FXS, Genetic testing, UnitedHealth Group, Pharmaceutical Research and Manufacturers of America, Sibling, DMD, Alexion Pharmaceuticals, HIV disease progression rates, American College of Medical Genetics and Genomics, Patient, Pediatrics, Physician, Clutch (eggs), Sanofi, Rare, Amicus Therapeutics, Mortality, Infant, American College, Medical genetics, Disease, Medical imaging, Medical device, Pharmaceutical industry, SCID, Genomics, Genentech, Ultragenyx, Optum, Policy

This new study on the Cost of Delayed Diagnosis is a follow-up to the landmark 2021 “ National Economic Burden of Rare Disease Study ,” which estimated that the economic impact of 379 rare diseases in 2019 was nearly $1 trillion, with 60% of those costs being shouldered directly by families and society.

Key Points: 
  • This new study on the Cost of Delayed Diagnosis is a follow-up to the landmark 2021 “ National Economic Burden of Rare Disease Study ,” which estimated that the economic impact of 379 rare diseases in 2019 was nearly $1 trillion, with 60% of those costs being shouldered directly by families and society.
  • “Medical costs for rare diseases are inevitable, but avoidable costs from delayed diagnosis not only place financial strain on individuals and families but also divert crucial healthcare funds.
  • For individuals with late onset Pompe disease, delayed diagnosis increased mean annual direct medical costs in the year of diagnosis by approximately $50,000 per patient compared with timely diagnosis.
  • For more information about “Cost Benefits of Early Diagnosis and Screening in Rare Disease” study, visit the study website at everylifefoundation.org/delayed-diagnosis-study .

Ascent Solar Technologies, Inc. Achieves New Benchmark of 15.5% in Cell Production Efficiency of its CIGS Solar Technology

Retrieved on: 
Tuesday, September 12, 2023
ASTI, CIGS, ALD, Renewable energy

THORNTON, Colo., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Ascent Solar Technologies, Inc. (NASDAQ: ASTI) (“ASTI” or the “Company”), the leading U.S. innovator in the design and manufacture of featherweight, flexible thin-film photovoltaic (PV) solutions, announced today that it has achieved a cell production efficiency increase, with a new benchmark of 15.5% in its CIGS solar technology, a significant increase from the 10.8% standard efficiency measured for production material in 2012.

Key Points: 
  • THORNTON, Colo., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Ascent Solar Technologies, Inc. (NASDAQ: ASTI) (“ASTI” or the “Company”), the leading U.S. innovator in the design and manufacture of featherweight, flexible thin-film photovoltaic (PV) solutions, announced today that it has achieved a cell production efficiency increase, with a new benchmark of 15.5% in its CIGS solar technology, a significant increase from the 10.8% standard efficiency measured for production material in 2012.
  • This increase is the result of focused innovation and a giant step toward the improved efficiencies that ASTI intends to deliver through continued process optimization and development of alternate chemistries.
  • ASTI expects to see an even greater increase in cell efficiency through the use of zinc oxysulfide, implemented through an Atomic Layer Deposition (ALD) process, which could potentially increase overall cell production efficiency by an additional 1% to 1.5%.
  • “We are thrilled with the rapid progress optimization for our CIGS technology that has taken place over just a few short weeks,” said Paul Warley, ASTI’s Chief Executive Officer.

SkyWater Installs Atomic Layer Deposition System for Development and Production of Advanced Technologies

Retrieved on: 
Thursday, September 7, 2023
Mobile, Wireless, Technology, Security, Engineering, Software, Manufacturing, Networks, Government Technology, Electronic Design Automation, Defense, SkyWater Technology, Aluminium nitride, Titanium dioxide, ALD, Mobility as a service, ATS, Silicon dioxide, CMOS, Applied Materials, Silicon, Zirconium dioxide, 3D printing, Powder metallurgy

SkyWater Technology (NASDAQ: SKYT), the trusted technology realization partner, today announced it will offer customers a new semiconductor processing tool for atomic layer deposition (ALD), the Applied® Picosun® MorpherTM.

Key Points: 
  • SkyWater Technology (NASDAQ: SKYT), the trusted technology realization partner, today announced it will offer customers a new semiconductor processing tool for atomic layer deposition (ALD), the Applied® Picosun® MorpherTM.
  • By offering the AppliedPicosun Morpher ALD tool from Picosun , an Applied Materials company, SkyWater will provide customers access to this unique capability.
  • ALD is an advanced thin film deposition process which is used to fabricate ultra-thin, highly uniform and conformal material layers for various applications.
  • The tool being installed at SkyWater is configured with two thermal batch chambers for maximum capability and production throughput.

Mass-Vac Introduces MV Multi-Trap® 16" High-Capacity Vacuum Inlet Trap for Heavy Contaminant Vacuum Prodcesses

Retrieved on: 
Tuesday, September 5, 2023
HVPE, CFM, PECVD, MV, LPCVD, ALD, MOCVD, Dredging

NORTH BILLERICA, Mass., Sept. 5, 2023 /PRNewswire-PRWeb/ -- Mass-Vac, Inc. has introduced a high-capacity vacuum pump inlet trap designed to remove high quantities of contaminants from LPCVD, PECVD, MOCVD, HVPE, ALD and similar processes.

Key Points: 
  • Providing a conductance of > 2000 CFM @ 1 TORR, the MV Multi-Trap® 16" High-Capacity Vacuum Inlet Trap can be supplied with 25- and 100-micron polyester ratings.
  • The MV Multi-Trap® 16" High-Capacity Vacuum Inlet Trap for heavy contaminant producing processes features a stainless steel housing with a large knockdown stage and a large pleated filter made from high-temperature polyester to capture and retain large quantities of particulates.
  • Providing a conductance of > 2000 CFM @ 1 TORR, the MV Multi-Trap® 16" High-Capacity Vacuum Inlet Trap can be supplied with 25- and 100-micron polyester ratings.
  • The MV Multi-Trap® 16" High-Capacity Vacuum Inlet Trap is priced from $4,975.00 (list) complete.

Poxel Reports Cash and Revenue for the Second Quarter and First Half 2023 and Provides Corporate Update

Retrieved on: 
Wednesday, August 30, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diabetes, ULF, Senior, Adrenoleukodystrophy, Prescription, Plasma, JPY, Patent, Patient, Serono, Merck, R, Estonia, POC, Pioglitazone, Sumitomo Group, Disease, Male, NASH, Pharmacokinetics, USD, EPO, Fatty liver disease, Leukodystrophy, Marshal of France, Rare, Kidney, Conference, Safety, Abstract, DPP4, ALD, JDS, Merck Serono, European Patent Office, Biomarker, DSM-IV codes, Communication, AMN, IRIS, Scientific communication, Sumitomo Pharma, United States patent law, SGLT2, VLCFA, European Patent Convention, Pharmacology, TZD, Pharmaceutical industry, Medical device, Cryptocurrency, Imeglimin, EUR, Euronext

These factors have resulted in a much higher increase in demand for TWYMEEG than expected by Sumitomo, and thus inventories are temporarily tight.

Key Points: 
  • These factors have resulted in a much higher increase in demand for TWYMEEG than expected by Sumitomo, and thus inventories are temporarily tight.
  • For the Sumitomo FY 2023, as a conservative assumption in line with Sumitomo’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • As of June 30, 2023, cash and cash equivalents were EUR 7.6 million (USD 8.2 million), as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.